Literature DB >> 21885418

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis.

M Villar, G Sotgiu, L D'Ambrosio, E Raymundo, L Fernandes, J Barbedo, N Diogo, C Lange, R Centis, G B Migliori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21885418     DOI： 10.1183/09031936.00195210

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  18 in total

1.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Authors:  Adrian Rendon; Simon Tiberi; Anna Scardigli; Lia D'Ambrosio; Rosella Centis; Jose A Caminero; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 4.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

Review 5.  Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

Authors:  Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Marina Tadolini; Margareth Dalcolmo; Adrian Rendon; Susanna Esposito; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

6.  An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.

Authors:  Amit Kaushik; Abigail M Heuer; Drew T Bell; Jeffrey C Culhane; David C Ebner; Nicole Parrish; J Thomas Ippoliti; Gyanu Lamichhane
Journal:  Bioorg Med Chem Lett       Date:  2016-06-09       Impact factor: 2.823

7.  In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors:  Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

Review 8.  WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Cheuk-Ming Tam; Chi-Chiu Leung
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

9.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

10.  Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.

Authors:  Kristina M Bigelow; Amelia N Deitchman; Si-Yang Li; Kala Barnes-Boyle; Sandeep Tyagi; Heena Soni; Kelly E Dooley; Rada M Savic; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.